Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis

  title={Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis},
  author={Sara Morsy and Samar Morsy Khalil and Mohamed Fahmy Doheim and Mohamed Gomaa Kamel and Doaa Saeed Mahmoud El-Basiony and Hossam Idrees Ahmed Hassan and Ahmed Abdelaziz Eisa and Cao Thị Anh Ngoc and Nguyen Phu Dang and Kenji Hirayama and Nguyen Tien Huy},
  journal={Acta Neuropsychiatrica},
  pages={175 - 185}
Abstract Objective: After MRI studies suggested the efficacy of ethyl-EPA in reducing the progressive brain atrophy in Huntington disease (HD), trials were conducted to test its efficacy as a treatment for HD. Trials that continued for 6 months did not find any significant improvement, urging discontinuation of the drug. However, trials that continued for 12 months indicated improvement of motor functions in these patients. Methods: We searched 12 electronic databases to find randomised… 
3 Citations
ISSN: 2595-6825
It can be identified, in general, that the association between cognitive decline and infratentorial brain neoplasms is due to the form of treatment normally suggested to deal with this disease.
Deep Hypothermic Circulatory Arrest in the Pediatric Population Undergoing Cardiac Surgery With Electroencephalography Monitoring: A Systematic Review and Meta-Analysis.
Electroencephalogram seizures were found to be associated with increased neurologic abnormalities and neurodevelopmental delay, and EEG seizures were more common than clinical seizures.


Ethyl-EPA in Huntington disease
Ethyl-eicosapentaenoate (ethyl-EPA) (purity >95%) had no benefit in the intent-to-treat cohort of patients with Huntington disease, but exploratory analysis revealed that a significantly higher number of patients in the per protocol cohort, treated with ethyl-EPA, showed stable or improved motor function.
MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment
It is concluded that treatment with ethyl-EPA is associated with beneficial motor and MRI changes and was associated with a reverse process in patients with advanced Huntington's disease.
Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study.
Ethyl-EPA was not beneficial in patients with Huntington disease during 6 months of placebo-controlled evaluation, and no differences were found in measures of function, cognition, or global impression.
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives and may therefore lead to stable systemic exposure while preserving key pharmacological activity in patients with Huntington disease.
Reduction in Cerebral Atrophy Associated with Ethyl-Eicosapentaenoic Acid Treatment in Patients with Huntington's Disease
Findings show that treatment with ethyl-EPA is associated with significant reduction in brain atrophy, particularly in the caudate and thalamus, no other drug tested in Huntington's disease has shown this effect.
The incidence and prevalence of Huntington's disease: A systematic review and meta‐analysis
The aim of this study was to estimate the incidence and prevalence of HD through a systematic review of the literature, and revealed a significantly lower prevalence in Asia, compared to European, North American, and Australian populations.
Ethyl-EPA in Huntington disease—Potentially relevant mechanism of action
Short‐term effects of tetrabenazine on chorea associated with Huntington's disease
During short‐term follow-up after a single dose of tetrabenazine, TBZ improves chorea for approximately 5 hours, and this effect is similar to that of a double dose.
Unified Huntington's disease rating scale: A follow up
The authors suggest performing a total UHDRS evaluation every second year for every HD patient as part of the routine longitudinal evaluation.